Drug Update · Oncology

FDA Approves Sonrotoclax for Relapsed or Refractory Mantle Cell Lymphoma: 52% ORR

August 10, 2026

Overall response rate (ORR)

52% (95% CI: 42, 62)

Median duration of response (DOR)

15.8 months (95% CI: 7.4, not estimable)

Median time to response

1.9 months

Trial

BGB-11417-201 (NCT05471843), single-arm, 103 adults

FDA approval date

05/13/2026

Approved dose

Four-week ramp-up then 320 mg orally once daily

Serious adverse reactions

37% (pneumonia 10%) in 115 patients evaluated for safety

Clinical Perspective

Hematologists and medical oncologists who treat adults with relapsed or refractory mantle cell lymphoma after at least two prior systemic therapies, including a BTK inhibitor, are the primary clinicians affected by this approval ^[3]. The FDA’s accelerated approval supports use of sonrotoclax as an oral BCL-2 inhibitor option in this heavily pretreated MCL population, with efficacy established by an ORR of 52% and a median DOR of 15.8 months in a single-arm study ^[3]. Will ongoing randomized confirmatory trials clarify whether sonrotoclax plus a BTK inhibitor improves progression-free survival compared with BTK inhibitor therapy alone?

Dr. Meera Pillai · Oncology

The FDA granted accelerated approval to sonrotoclax (Beqalzi, BeOne Medicines USA, Inc.) on May 13, 2026, for adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor ^[3]. The approval was based on BGB-11417-201, a single-arm multicenter trial that showed an overall response rate (ORR) of 52% (95% CI: 42, 62) as assessed by an independent review committee ^[3].

Clinical Context

Sonrotoclax is a BCL-2 inhibitor approved by the FDA for relapsed or refractory MCL after at least two prior systemic therapies including a BTK inhibitor; the sponsor for the U.S. approval is BeOne Medicines USA, Inc. ^[3]. BCL-2 inhibitors act by disrupting interactions between BCL2 and proapoptotic proteins to promote apoptosis in malignant cells, a mechanism described for first-generation agents such as venetoclax in hematologic malignancies ^[1]^[2]. Preclinical data reported that sonrotoclax demonstrated stronger cytotoxic activity and more profound tumor growth inhibition than venetoclax in multiple hematologic tumor models and effectively inhibited venetoclax-resistant BCL2 variants such as G101V, with structural data showing a novel P2 pocket binding mode ^[1]. Sonrotoclax was under clinical investigation prior to this accelerated approval ^[1]^[3].

Key Findings

The single-arm BGB-11417-201 trial showed sonrotoclax achieved an overall response rate (ORR) of 52% (95% CI: 42, 62) in adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a BTK inhibitor ^[3].
Median time to response in BGB-11417-201 was 1.9 months as assessed by an independent review committee ^[3].
Median duration of response (DOR) was 15.8 months (95% CI: 7.4, not estimable) after an estimated median follow-up of 11.9 months ^[3].
The FDA-approved regimen begins with a four-week ramp-up phase to reduce tumor lysis syndrome risk, followed by sonrotoclax 320 mg taken orally once daily until disease progression or unacceptable toxicity ^[3].
Clinicians should consult current prescribing information for full dosing guidance.

Safety & Tolerability

Tumor lysis syndrome (TLS) is included as a warning and precaution in the prescribing information for sonrotoclax ^[3].
Serious infections are a listed warning and precaution ^[3].
Neutropenia is a listed warning and precaution ^[3].
In 115 patients with MCL evaluated for safety, serious adverse reactions occurred in 37%, most frequently pneumonia (10%) ^[3].

Study Design

The FDA approval was based on BGB-11417-201 (NCT05471843), a single-arm, multicenter trial that enrolled 103 adults with relapsed or refractory mantle cell lymphoma who previously received anti-CD20–based therapy and a BTK inhibitor ^[3]. Efficacy was established on ORR and DOR as assessed by an independent review committee using Lugano criteria; median follow-up was estimated at 11.9 months ^[3]. The FDA granted accelerated approval and outlined a postmarketing requirement for a randomized confirmatory trial to verify clinical benefit, randomizing patients to sonrotoclax plus zanubrutinib versus placebo plus zanubrutinib with primary endpoint PFS ^[4].

FAQ

Q1 What is sonrotoclax (Beqalzi) approved for?

Sonrotoclax (Beqalzi) is approved under accelerated approval for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. The approval was granted by the FDA on May 13, 2026, based on response rate and duration of response data from a single-arm multicenter trial.

Q2 How does sonrotoclax work?

Sonrotoclax is a BCL-2 inhibitor that targets the antiapoptotic protein BCL2 to disrupt its interaction with proapoptotic proteins and promote apoptosis in malignant cells. Preclinical studies reported that sonrotoclax demonstrated stronger cytotoxic activity than venetoclax in multiple hematologic tumor models and inhibited venetoclax-resistant BCL2 variants such as G101V, with structural data showing a novel binding mode in the BCL2 P2 pocket.

Q3 What is the recommended dose of sonrotoclax?

The FDA-approved regimen begins with a four-week ramp-up phase to reduce the risk of tumor lysis syndrome, followed by sonrotoclax 320 mg taken orally once daily until disease progression or unacceptable toxicity, per the prescribing information. Clinicians should consult current prescribing information for full dosing guidance.

Q4 What are the most common or notable side effects?

The FDA prescribing information includes warnings and precautions for tumor lysis syndrome, serious infections, and neutropenia. In the safety population of 115 patients with MCL, serious adverse reactions occurred in 37%, with pneumonia reported in 10% of patients. Providers should follow the prescribing information for monitoring and management recommendations.

Clinicians should consult current prescribing information for full dosing guidance.

FDA Approves Sonrotoclax for Relapsed or Refractory Mantle Cell Lymphoma: 52% ORR

Direct Clinical Takeaway & Evidence Summary

FDA Approves Sonrotoclax for Relapsed or Refractory Mantle Cell Lymphoma: 52% ORR

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly clinical updates for Oncology in your inbox.

Related Clinical Updates

Camizestrant at FDA ODAC April 30, 2026: SERENA-6 Showed PFS 16.0 vs 9.2 Months (HR 0.44)

FDA Approves relacorilant for Platinum-Resistant Ovarian Cancer; PFS HR 0.70 (ROSELLA)

FDA Approves vepdegestrant for ESR1‑Mutated ER+ HER2‑ Breast Cancer; PFS HR 0.58 in VERITAC‑2

Verified HCP Portal